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A recurrent de novo missense pathogenic variant in
SMARCB1 causes severe intellectual disability and choroid
plexus hyperplasia with resultant hydrocephalus
Illja J. Diets, MD1, Trine Prescott, MD, PhD2, Neena L. Champaigne, MD3,
Grazia M. S. Mancini, MD, PhD4, Bård Krossnes, MD5, Radek Frič, MD, PhD6, Kristina Kocsis7,
Marjolijn C. J. Jongmans, MD, PhD1,8,9 and Tjitske Kleefstra, MD, PhD1,10
Purpose: SMARCB1 encodes a subunit of the SWI/SNF complex
involved in chromatin remodeling. Pathogenic variants (PV) in this
gene can give rise to three conditions. Heterozygous loss-of-
function germline PV cause rhabdoid tumor predisposition
syndrome and schwannomatosis. Missense PV and small in-
frame deletions in exons 8 and 9 result in Coffin–Siris syndrome,
which is characterized by intellectual disability (ID), coarse facial
features, and fifth digit anomalies.
Methods: By a gene matching approach, individuals with a similar
SMARCB1 PV were identified. Informed consent was obtained and
patient data were collected to further establish genotype–phenotype
relationship.
Results: A recurrent de novo missense PV (c.110G>A;p.Arg37His)
in exon 2 of SMARCB1, encoding the DNA-binding domain, was
identified in four individuals from different genetic centers. They
shared a distinct phenotype consisting of profound ID and
hydrocephalus due to choroid plexus hyperplasia. Other shared
features include severe neonatal feeding difficulties; congenital
heart, kidney, and eye anomalies; obstructive sleep apnea; and
anemia.
Conclusion: The p.Arg37His PV in the DNA-binding domain of
SMARCB1 causes a distinctive syndrome, likely through a gain-of-
function or dominant-negative effect, which is characterized by
severe ID and hydrocephalus resulting from choroid plexus
hyperplasia. This report broadens the phenotypic spectrum
associated with PV in SMARCB1.
Genetics in Medicine (2019) 21:572–579; https://doi.org/10.1038/s41436-
018-0079-4
Keywords: SMARCB1; Intellectual disability; Hydrocephalus;
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INTRODUCTION
The SMARCB1 (MIM 601607; GenBank: NM_003073.3)
gene, located on chromosome 22q11.23 and consisting of
nine exons, encodes a subunit of the switch/sucrose
nonfermenting (SWI/SNF) complex involved in chromatin
remodeling.1 The SWI/SNF complex, also known as the BAF
complex, is an adenosine triphosphate (ATP)-dependent
chromatin remodeling complex involved in the regulation of
gene accessibility and expression.2 This complex is involved in
mobilizing the histone–DNA bond using energy generated
from ATP hydrolysis, causing nucleosome sliding, dissocia-
tion, or replacement.3 By altering histone configuration,
SMARCB1 and the SWI/SNF complex are involved in both
activation and repression of target genes.
Three autosomal dominant conditions are caused by
germline pathogenic variants (PV) in SMARCB1. Loss-of-
function PV cause rhabdoid tumor predisposition syndrome
type 1 (RTPS1) (MIM 609322),4-6 which is characterized by
the development of highly aggressive tumors in young
children, mainly atypical teratoid/rhabdoid tumors (AT/RT)
of the brain and malignant rhabdoid tumors of the kidney and
soft tissue. Loss-of-function and missense alterations are also
found in both families and sporadic patients with schwanno-
matosis (MIM 162091).7,8 Patients develop mainly benign
cranial and peripheral nerve sheath tumors. Recent work in
mice suggests that early SMARCB1 loss causes rhabdoid
tumors, whereas a loss at later stages combined with NF2
gene inactivation causes schwannomas.9 Lastly, missense
PV and small in-frame deletions in exons 8 and 9
of the gene are a cause of Coffin–Siris syndrome
(CSS) (MIM 614608), a syndrome defined by intellectual
disability (ID), coarse facial features, feeding difficulties and
fifth digit anomalies. Because no truncating PV have been
reported in CSS, these PV are thought to exert their effect
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through a gain-of-function or dominant-negative mechan-
ism,10,11 but no functional studies have been performed.
Approximately 7% of individuals with CSS carry a PV in
SMARCB1.11-13 CSS can also result from PV in other subunits
of the SWI/SNF complex, but individuals with a PV in
SMARCB1 are, in general, the most severely affected.10
Known pathogenic PV causing these three syndromes are
shown in Fig. 1. Some patients and families carrying a
SMARCB1 PV presented with more than one of the above
described conditions, such as a family with both rhabdoid
tumors and schwannomas14 and a patient with CSS who
developed schwannomas.15
Previously, we identified a de novo p.Arg37His PV in
SMARCB1 in an individual with a clinical presentation
overlapping with Kleefstra syndrome (KS) (MIM 610253),16
We have now identified three additional patients with the
same PV, who show a strikingly similar phenotype consisting
of severe intellectual disability (ID), hydrocephalus due to a
choroid plexus hyperplasia, various congenital anomalies, and
feeding difficulties. In this report, we describe the four
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Fig. 1 Known pathogenic variants in patients with rhabdoid tumor predisposition syndrome, schwannomatosis, and Coffin–Siris syndrome. a
Detailed view of the SMARCB1 gene (GenBank: NM_003073.3) and the reported deletions and duplications in rhabdoid tumor predisposition syndrome
type 1 (RTPS1). ¥= one of the duplications of exon 6 represents a family with an overlapping phenotype of both atypical teratoid/rhabdoid tumors and
schwannomas. b Overview of SMARCB1 including the DNA-binding and SNF5 domain and the location of known pathogenic variants on a protein level in
patients with RTPS1 (in yellow, based on report of Eaton et al.,30) schwannomatosis (in green, based on reports of Smith et al.,31,32 Sestini et al.,28 Hadfield
et al.,7 Boyd et al.33 and Rousseau et al.,34) Coffin–Siris syndrome (in red, based on reports of Tsurusaki et al.,11,35 Santen et al.,12 and Wieczorek et al.13),
and an overlapping phenotype of multiple of these phenotypes (in purple). The patients with overlapping phenotypes are two families with both atypical
teratoid/rhabdoid tumors (AT/RTs) and schwannomas (p.Gln123* and p.Arg158*) and a male with both Coffin–Siris syndrome and schwannomas (p.
Arg374Gln)
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individuals, which broadens the spectrum of disorders
associated with PV in SMARCB1.
SUBJECTS AND METHODS
The first patient was identified by exome sequencing (ES) in a
cohort of EHMT1-negative patients within the Kleefstra
syndrome phenotypic spectrum (KSS).16 Approval for this
study was obtained from the institutional ethical board at
Radboud University Medical Center, Commissie Mensgebon-
den Onderzoek Regio Arnhem-Nijmegen (NL36191.091.11).
Approval was also obtained to publish patient photos. Three
additional individuals were identified in different genetic centers
by trio ES in a diagnostic setting as previously described.17
Details are available upon request. In all four patients, ES was
indicated because of severe intellectual disability in combination
with congenital anomalies. ES was performed when patients
visited the clinical genetics department at ages 9 years, 5 years,
12 years, and 17 months, respectively. Informed consent was
obtained from parents and clinical information and photo-
graphs were collected (Fig. 2). Magnetic resonance images
(MRIs) were collected and re-evaluated.
RESULTS
By ES, four females were identified with a recurrent de novo
missense PV in SMARCB1 (c.110G>A; p.Arg37His). No other
possible explanatory variants were found with ES. The four
patients share a distinctive phenotype, which is discussed in
more detail in the following case reports and summarized in
Table 1.
Patient 1 was previously described by Kleefstra et al.16 She
was born to healthy non consanguineous parents at 36 weeks
of gestation with a birth weight of 2400 grams after an
uncomplicated pregnancy. The neonatal period was
complicated by feeding difficulties. She developed hydroce-
phalus as a result of an abnormally high production of
cerebrospinal fluid (CSF) due to choroid plexus hyperplasia,
for which a ventriculoperitoneal shunt was placed at the age of
2.5 years. At that age, she had severe ID and was not able to sit
or speak any words. A brain MRI showed moderately enlarged
ventricles, decreased volume of the pons and brainstem and an
enlarged choroid plexus (Fig. 3). Multiple shunt revisions were
performed, and a partial choroid plexectomy was needed at
age 8 years to reduce the CSF production. Histopathological
examination of intraventricular tissue removed at surgery was
consistent with a diagnosis of choroid plexus papilloma
(Fig. 4). Immunohistochemical staining of the papilloma with
INI1/SMARCB1 antibodies (purified mouse anti-BAF47, BD
Transduction Laboratories, product number 612110) was
performed, to determine if there was loss of INI1/SMARCB1
expression in the tumor as seen in AT/RTs. We observed weak
staining of INI1/SMARCB1, with no difference between the
tumor cells and the endothelial cells (data not shown). The
child has visual impairment, strabismus, and myopia
(approximately -7 diopters bilaterally). She has signs of sleep
apnea with pauses in breathing at night, but does not require
oxygen. She has a history of unexplained intermittent
microcytic anemia (lowest Hb 4.3mmol/L at age 2 and 4.9
mmol/L at age 14, mean corpuscular volume (MCV) 68).
At the age of 9.5 years, her height was 144 cm (0 SD),
weight 31 kg (−1 SD) and head circumference 52.4 cm (0 SD).
She has an extra skin fold adjacent to one of her labia minora.
A cardiac ultrasound showed no abnormalities. She has
truncal hypotonia, and does not walk, but is independently
mobile in a wheelchair. She does not speak, but has well-
developed nonverbal communication skills. She is a socially
aware and friendly teenager.
Patient 1 Patient 2 Patient 3 Patient 4
2y 3y 1y
14y 6.5y 12y
2y
Fig. 2 Clinical characteristics of patients with a p.Arg37His pathogenic variant in SMARCB1. Frontal pictures of the four patients with a de novo p.
Arg37His pathogenic variant in SMARCB1. Patients share a hypotonic facies, upslanted palpebral fissures, round nasal tip, and large mouth. In patients 1
and 3, diastema of the upper incisors is seen. In patients 1 and 4, midface hypoplasia and tongue protrusion is seen
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Patient 2 was born to healthy non consanguineous parents
after a pregnancy complicated by gestational diabetes. A
prenatal ultrasound showed mild ventriculomegaly. She was
born at 37 weeks gestation with a birth weight of 2990 grams.
She had severe feeding difficulties and has required total
parental nutrition and gastrojejunal tube feeding since the age
of 15 months. She developed hydrocephalus for which she was
treated with a ventriculoperitoneal shunt at the age of
8 months. She has undergone multiple shunt revisions. A
brain MRI showed hydrocephalus with choroid plexus
hyperplasia, in addition to a thin corpus callosum and
hippocampal atrophy. When examined at the age of 6 years,
she had severe ID, was nonambulatory, and spoke no words.
She had cortical visual impairment, no light perception,
vertical intermittent nystagmus and multiple additional eye
problems such as a cataract (diagnosed at age 3) and detached
retina of the right eye (both surgically corrected) and a
hyphema of the left eye of unknown origin. She had
generalized hypotonia with joint hypermobility and a
persistent knee dislocation. Cardiac ultrasound showed a
bicuspid aortic valve, mild aortic dilation, and an atrial septal
defect. With abdominal ultrasound, severe bilateral vesicour-
eteral reflux was diagnosed. At night, she required bilevel
positive airway pressure (BiPAP) for central sleep apnea. She
had positional deformities of the feet, a history of kidney
stones, and precocious puberty with acne and pubic hair at
the age of 4 years. She had a history of mild macrocytic
anemia (lowest Hb 6.3 mmol/L at age 4, MCV 90.8), for which
she was placed on iron suppletion. Physical examination at
the age of 6 years showed a height of 122 cm (96th centile),
weight of 20.8 kg (67th centile), and head circumference of 49
cm (7th centile). She had limited social awareness and was
nonverbal, but she could vocalize. She passed away at the age
of 6 years after having progressive gastrointestinal dysmotility
with inability to tolerated enteral nutrition.
Patient 3 was born to healthy non consanguineous parents
at 41 weeks gestation with a birth weight of 3145 grams and a
head circumference of 34 cm, after a pregnancy complicated
Table 1 Clinical features
Patient 1 Patient 2 Patient 3 Patient 4 Count features
Pathogenic variant c.110G>Ap.Arg37His c.110G>Ap.Arg37His c.110G>Ap.Arg37His c.110G>Ap.Arg37His
Inheritance De novo De novo De novo De novo
Age at examination 9.5 y 5 y 8 mo 12 y 17 mo
Development
Intellectual disability Severe Severe Severe Severe 4/4 (100%)
Speech delay Severe Severe Severe Severe 4/4 (100%)
Motor delay Severe Severe Severe Severe 4/4 (100%)
Congenital anomalies
Congenital heart defect - + - + 2/4 (50%)
Laryngomalacia - - - + 1/4 (25%)
Kidney anomalies - + + + 3/4 (75%)
Genital anomalies + - + - 2/4 (50%)
Neurological
Childhood hypotonia + + + + 4/4 (100%)
Hydrocephalus + + +/- (ICP) + 4/4 (100%)
Eye and ear abnormalities
CVI + + - + 3/4 (75%)
Myopia + ND + + 3/3 (100%)
Eye movement disorder - + + + 3/4 (75%)
Other eye problems + + + + 4/4 (100%)
Hearing loss - + - + 2/4 (50%)
Musculoskeletal
Brachycephaly + - - + 2/4 (50%)
Joint hypermobility - + + + 3/4 (75%)
Hip dysplasia - - - + 1/4 (25%)
Contractures + - + - 2/4 (50%)
Other
Obstructive sleep apnea + + + + 4/4 (100%)
Precocious puberty - + - N/A 1/3 (33%)
(History of) anemia + + + - 3/4 (75%)
Thrombocytopenia - - - + 1/4 (25%)
ICP increased intracranial pressure, CVI cortical visual impairment, ND not determined, N/A not applicable
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by intrauterine growth retardation. She was admitted to the
hospital neonatally because of respiratory and feeding
difficulties and hypotonia. A brain MRI showed ventriculo-
megaly with choroid plexus hyperplasia, a thin corpus
callosum, thin pons, and mild cerebellar vermis atrophy
(Fig. 3). She has high myopia (-14/-15 diopters), strabismus,
limited abduction of the left eye, and nystagmus. In the first
months of her life she had mild sleep apnea, which resolved
subsequently. She had severe vesicoureteral reflux requiring
nephrectomy at the age of 3 years. In addition, she had a
history of transient microcytic iron deficiency anemia (lowest
Hb 5.5 mmol/L at age 3, MCV 71). At the age of 6 years, eye
fundus examination showed papillary edema that later
resolved, compatible with mild increased intracranial pressure
for which no surgical intervention was needed. Repeat MRIs
at the age of 6 years and 12 years showed global atrophy,
enlarged CSF spaces, and choroid plexus hyperplasia. Physical
examination at the age of 12 years showed a height of 150 cm
(−1 SD) and head circumference of 52 cm (−1 SD). There is
no speech development, but she can reproduce musical
sounds of songs. She is able to stand with support.
Patient 4 was born to healthy non consanguineous parents
after a pregnancy complicated by polyhydramnios. A prenatal
ultrasound showed borderline enlarged cerebral ventricles.
After an uncomplicated delivery at 39 weeks of gestation, she
was admitted to the neonatal intensive care unit, where she
was diagnosed with laryngotracheomalacia and partial vocal
cord paralysis, which was surgically corrected. A cardiac
ultrasound showed an atrial septal defect and a patent ductus
arteriosus, which were also corrected surgically. Brain MRI
showed a foreshortened corpus callosum, and choroid plexus
hyperplasia with hydrocephalus. At age 7 months, her
hydrocephalus was treated with a shunt, later revised at two
occasions. Severe central obstructive sleep apnea was
diagnosed, which required tracheostomy in addition to BiPAP
and oxygen supply at night. She had feeding difficulties that
required G-tube placement. She underwent exploratory
surgery for concerns for a malrotated gut, during which an
ectopic appendix was identified and removed. She has poor
visual tracking and myopia, in addition to moderate
sensorineural hearing loss. Furthermore, she has hypotonia,
joint hypermobility, congenital hip dysplasia that required
splinting, and mild hydronephrosis. She was admitted to the
hospital because thrombocytopenia was identified by a
complete blood count performed because of lethargy.
Immune thrombocytopenic purpura (ITP) was diagnosed,
and she received intravenous immunoglobulins, after which
the platelet count normalized. Physical examination at the age
of 2 years showed a height of 80.5 cm (52nd centile), weight of
11.4 kg (82nd centile), and head circumference of 50 cm (99th
centile).
In all four girls, a recurrent de novo missense PV was
identified (c.110G>A; p.Arg37His) by ES. This PV affects a
highly conserved residue in exon 2 of the SMARCB1 gene. It is
predicted to result in the replacement of an arginine residue
by histidine, leading to a loss of charge.18 In silico analysis was
PATIENT 1
a b
e
PATIENT 3 PATIENT 4
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h
T1, age 8 years T1, age 2 months T1, age 12 years Flair, age 7 months
T2, age 8 years T2, age 2 months T2, age 12 years T1, age 7 months
Fig. 3 Representative magnetic resonance images (MRIs) of patients with a p.Arg37His pathogenic variant in SMARCB1. a, e Patient 1, MRIs at
age 8 years. a T1 sagittal section shows the thin corpus callosum, the drain and enlarged cisterna magna. e T2 axial section shows enlarged ventricles,
choroid plexus hyperplasia and reduced peripheral cerebral spinal fluid spaces. b, c, f, g Patient 3, MRIs at (b, f) age 2 months and (c, g) age 12 years. b, c
T1 sagittal midline sections show a thin corpus callosum, thin pons and mild cerebellar vermis atrophy. f, g T2 axial sections show a progressive enlargement
of the lateral ventricles and hyperplasia of the choroid plexus in time. d, h Patient 4, MRIs at age 7 months. d Sagittal cube fluid-attenuated inversion
recovery (FLAIR) section shows a thin and stretched corpus callosum; thin pons, mesencephalon, and medulla oblongata; and small cerebellar vermis with
enlarged fourth ventricle and cisterna magna. h T1 axial section shows dilated lateral ventricles and choroid plexus hyperplasia
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performed with SIFT,19 Mutation Taster,20 and PolyPhen-221
prediction programs, which all predicted the PV to be
deleterious. The PV was not reported before in our in-house
database of 15,576 exomes, nor in the databases ExAC,
gnomAD, GoNL, or the Exome Variant Server (EVS).
DISCUSSION
By ES and a subsequent gene matching approach, we have
identified four patients with a recurrent de novo p.Arg37His
PV in SMARCB1. They share a specific phenotype consisting
of severe ID and hydrocephalus due to choroid plexus
hyperplasia, in addition to anemia, sleep apnea, and
ophthalmologic problems. PV in SMARCB1 have previously
been reported as a cause of Coffin–Siris syndrome.11–13 PV
causing this syndrome are localized in the SNF5 domain on
the C-terminal end of the gene, between amino acids 363 and
377, and are presumably activating or dominant-negative PV
(Fig. 1).10,11 Because missense PV in the same region are also
found somatically in schwannomas, and because a CSS
patient with schwannomas has been described, a dominant-
negative effect might be more likely. However, no functional
studies have been performed to confirm this. The PV reported
here, however, is located at the N-terminal end of the gene,
within the DNA-binding domain of the protein, suggesting
that this PV might have a different effect and cause a different
phenotype.
Some similarities exist between individuals with CSS and
the patients described in this report, such as severe ID,
congenital heart defects, kidney anomalies, and feeding
difficulties. On the other hand, features that are frequently
noted in SMARCB1-based CSS are impaired growth, micro-
cephaly, fifth digit anomalies, scoliosis, and epilepsy, none of
which are present in the individuals we describe. Further-
more, the most distinctive phenotypic feature associated with
the p.Arg37His variant is enlargement of the central CSF
spaces, often leading to high-pressure hydrocephalus. This is
associated with choroid plexus hyperplasia and overproduc-
tion of cerebrospinal fluid, which has not been described in
patients diagnosed with CSS. This implies that our patients
represent a different entity within the spectrum of syndromes
associated with PV in SMARCB1.
In patients heterozygous for a p.Arg37His PV in SMARCB1,
clinicians should be aware of signs of increased and
progressive intracranial pressure. The most striking shared
feature in the cohort we describe is high-pressure hydro-
cephalus, which required shunting and multiple shunt
revisions in three individuals, as well as partial ablative
surgery in one. Neuroimaging reports were available for three
patients, showing choroid plexus hyperplasia in addition to
hydrocephalus, indicating that the hydrocephalus is a
consequence of increased production of cerebrospinal fluid
(Fig. 3). The choroid plexus was unilaterally resected in
patient 1, and histopathological analysis showed an under-
lying choroid plexus papilloma. In the past, families with PV
in SMARCB1 and choroid plexus carcinomas have been
described,5,22 but the current opinion is that these tumors
were actually atypical teratoid/rhabdoid tumors (AT/RTs),
with loss of SMARCB1 as the distinguishing feature between
these two types of tumors.23 Furthermore, no evidence has
been found for PV in SMARCB1 in choroid plexus
papilloma.24
Another rare feature present in all patients is sleep apnea,
which is most likely of central origin. Two patients require
BiPAP and oxygen supply at night, one of whom underwent a
tracheostomy in addition. This might be caused by increased
intracranial pressure due to hydrocephalus, however in two
patients the sleep apnea persisted after shunting of the
hydrocephalus. Furthermore, we noted a reduced volume of
the brainstem and pons, i.e., the structure containing centers
controlling the respiration (Fig. 3), which is an explanation
for sleep apnea. As sleep apnea can cause serious health
problems, performing a polysomnogram should be consid-
ered in these patients.
Several additional congenital anomalies and medical
problems were noted. Two girls had severe vesicoureteral
reflux disease, resulting in hydronephrosis and requiring a
a b c
Fig. 4 Histopathological examination of the choroid plexus in patient 1 showed a choroid plexus papilloma. Microphotographs are shown at a
magnification of 400× of the choroid plexus after it was partially resected in patient 1 at the age of 8 years. Thin sections from paraffin embedded tumor
were used for immunohistochemistry with the following antibodies: Ki-67 (monoclonal mouse antihuman Ki-67 antigen, dilution 1:100, Dako-Denmark
Agilent, product number M7240, Glostrup, Denmark), transthyretin (polyclonal rabbit antihuman prealbumin, dilution 1:3000, Dako-Denmark Agilent,
product number A0002, Glostrup, Denmark) and Ini-1 (purified mouse anti-BAF47, concentration 250 µg/mL, dilution 1:100, BD Transduction Laboratories,
product number 612110). a Hematoxylin-eosin staining showing that the tumor has the morphology of a choroid plexus papilloma. b Ki-67 shows a
proliferative activity that was lower than normal in choroid plexus papillomas. c The tumor was positive for transthyretin, as expected for a choroid plexus
papilloma
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nephrectomy in one, implying that performing an abdominal
ultrasound could be of added value. All four patients were
admitted to the hospital in infancy due to neonatal feeding
difficulties, and three continued to require gastrojejunal (GJ)
tube feeds afterward. In one individual, the inability to
tolerate enteral nutrition was the cause of death, emphasizing
the potential severity of feeding difficulties. Diverse eye
problems were reported in all children, including severe
myopia, absent vision, and eye movement disorders, in
addition to acute conditions like a detached retina, hyphema,
and papillary edema. Finally, three girls had a period of
transient anemia (lowest Hb values ranging from 4.3 to 6.3
mmol/L) and the fourth had severe ITP requiring treatment
with intravenous immunoglobulins, which indicates that a
routine complete blood count can be considered.
Clustering of PV or recurrence of a specific PV can be
indicative of a gain-of-function or dominant-negative effect on
the protein.25,26 In the N-terminal DNA-binding domain in
which the p.Arg37His PV is located, several conserved residues
including Arg37 are suspected to be functionally important.27
A histidine substitution can potentially influence the DNA-
binding capacity. As shown in Fig. 1, the Arg37His PV affects
an area of the protein where both missense and truncating PV
in schwannomatosis and RTPS1 patients have been described
frequently. The tumors of these patients are characterized by
loss of the second allele of SMARCB1, and in schwannomas in
addition biallelic somatic NF2 PV are observed.7,28,29 The two-
and four-hit loss-of-function mechanisms in these syndromes
plead against a dominant-negative effect of the p.Arg37His
PV, because a tumor phenotype like in the schwannomatosis
and RTPS1 patients would be expected if this was the case.
Therefore, we hypothesize that the de novo p.Arg37His PV in
SMARCB1 results in a gain of function.
Conclusion
We have identified four patients with a de novo p.Arg37His
PV in SMARCB1, with a distinctive phenotype different from
Coffin–Siris syndrome, consisting of severe ID, hydrocephalus
due to choroid plexus hyperplasia, and various additional
congenital defects. Patients identified with this specific de
novo PV need careful clinical monitoring.
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